Physician profile
James K Fullerton
NPI 1760575229
$5,157.64
in general payments reported to CMS, 2019-2025
10 companies · $2,453 in 2025
The $2,453 reported for 2025 was more than what 84% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $744 · 2021: $160 · 2022: $562 · 2023: $735 · 2024: $336 · 2025: $2,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,820 · Travel and Lodging: $1,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.04 |
| Travel and Lodging | $1,704.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $3,191.15 | 2020-2025 | Phasix Mesh |
| Endogastric Solutions, INC | $585.12 | 2019-2024 | Esophyx |
| Kerecis Limited | $332.43 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Intuitive Surgical, INC. | $283.28 | 2022-2024 | Da Vinci Surgical System |
| Tela Bio, INC. | $198.33 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Stryker Corporation | $170.03 | 2022 | |
| Medtronic, INC. | $132.17 | 2023-2025 | Signia |
| Medline Industries LP | $116.13 | 2024 | |
| Micro-Tech Endoscopy USA, INC. | $101.25 | 2025 | |
| Covidien LP | $47.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fullerton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.